In AKI models induced by bovine serum albumin (BSA) and paraquat, RvD1 mimetics such as aspirin-triggered resolvin D1 (AT-RvD1) demonstrate therapeutic efficacy by reducing inflammatory cell infiltration in renal tissue, inhibiting NF-κB activation and inflammatory cytokine release, and activating the Nrf2 signaling pathway to upregulate antioxidant gene expression, thereby alleviating tubulointerstitial injury and fibrosis (66, 67). The gene discussed is NFKB1; the disease is acute kidney injury.